Navigation Links
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/27/2008

Extensive Clinical Development Program Investigating Golimumab in the

Treatment of These Diseases Serves as Basis for the Application

HORSHAM, Pa., June 27 /PRNewswire/ -- Centocor, Inc. announced today that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Golimumab, Centocor's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy. In February 2008, Centocor submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting the approval of golimumab as a monthly subcutaneous treatment for the same indications.

"This submission marks a major milestone in the clinical development program of golimumab, and we look forward to working with the FDA to bring golimumab to market," said Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "We remain focused on our commitment to innovation in the field of biomedicines, to addressing the ongoing needs of patients living with these debilitating diseases and to physicians in need of additional therapeutic options to effectively treat their patients."

Five pivotal Phase 3 trials support the BLA, which include the GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset (GO-BEFORE) study; the GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD) study; and A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Human Anti-TNF-alpha Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNF-alph
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
3. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
4. Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval
5. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
6. Phyhealth Submits HMO Applications with Required Federal and State Agencies
7. Takeda submits new drug application for alogliptin (syr-322) in the US
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
10. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
11. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... July 01, 2015 , ... Avid boxing style rock ... Jimi Hendrix Singer Bowl concert posters. The Who and the Rascals also played at ... According to Hawley, "The Doors played with the Who backing them up. The Doors ...
(Date:6/30/2015)... Atlanta, GA (PRWEB) , ... June 30, 2015 , ... ... salon niche, is expanding its suite of products to mobile teeth whitening entrepreneurs. Mobile ... or hair stylists that offer convenience and a personal touch. The popularity of the ...
(Date:6/30/2015)... Detroit, MI (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable ... The 44-year-old native of Detroit, MI, Kid Rock, is hitting the road again this summer ... rock, country, and hip hop superstar kicked off his summer tour this year at the ...
(Date:6/30/2015)... City, NJ (PRWEB) , ... June 30, 2015 , ... The American Institute of Personal ... Brown individually, the Top Ten Best Law Firm and Attorney Award respectively. As of ... as the type law firm and attorney in Northern New Jersey. The award is ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier this month ... Hyperbaric Medicine Course. Clinicians from WCA partnering hospitals across the country, met in ... Wound care and hyperbaric medicine education and training is something that is never ...
Breaking Medicine News(10 mins):Health News:Avid Boxing Style Rock Concert Poster Collector From Vintage Rock Posters Announces Search for 1968 Doors and Jimi Hendrix Singer Bowl Concert Posters 2Health News:White Blitz to Develop New Mobile Teeth Whitening Program for Entrepreneurs 2Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:JTB Law Group, LLC Recognized as a Top 10 Best Law Firm by AIOPIA 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3
... ... Areas, NEW YORK, March ... of Healthcare Providers and,Systems (HCAHPS) scores for hospitals nationwide on different aspects ... New York City scored well above the national average in both,overall patient ...
... Goal To Secure 1 Million Pledges By Independence ... the "Healing Starts With Us",national campaign launches its ... will mobilize and promote the campaign,s,goal to reach ... 2008., The campaign,s website comes after an ...
... Inc. (NYSE:,CNO) announced today that it has filed its ... 31, 2007 with the Securities and Exchange,Commission., The ... was $194.0,million, compared to the $210.1 million estimated by ... reported net loss applicable to,common stock for the fourth ...
... collateral damage from blood sugar disease , , FRIDAY, March ... of heart disease, stroke, blindness, kidney failure and non-traumatic ... than they normally do with age, a new study ... lung function as they grow older, research published in ...
... A child spikes a high fever, sometimes as high as ... to the emergency room, the hospital runs test after test, ... Many families though no one knows how many ... like clockwork, arent accompanied by any obvious symptoms and dont ...
... N.Y. -- For a rich source of stem cells to ... may one day look no further than the hair on ... month by University at Buffalo engineers. , Engineering ... blood vessels or regenerating new skin tissue using stem cells ...
Cached Medicine News:Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: